Share Price:

APNASPENAspen Pharmacare Hldgs1450531 (0.21%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Meet our people: Nicolas Lachèvre, IT OPS work‑study student at Aspen NDB

This month, the spotlight is not on systems or infrastructure, but on the person who brings them to life every day — Nicolas Lachèvre, Work‑Study Student in IT Operations at Aspen NDB.

Aspen Athletics Club shines at the Two Oceans Marathon

The Two Oceans Marathon once again brought together determination, camaraderie and athletic excellence—and Aspen Athletics Club delivered across both race days in Cape Town.

Aspen Group Chief Operations Officer highlights Aspen’s role at the World Bank & IMF spring meetings

Lorraine Hill, Aspen’s Group COO, attended the World Bank & IMF Spring Meetings in Washington, following an invitation from the IFC. Health and access featured strongly, including the World Bank’s Health Works initiative to expand quality, affordable healthcare by 2030.

Aspen Australia participates in the 2026 APP Conference

The Australian Pharmacy Professional Conference & Trade Exhibition (APP) once again brought together nearly 8,000 pharmacy professionals from across Australia — pharmacists, interns, students, assistants, and industry partners — for three days filled with learning, networking, and professional development. This year’s event was especially memorable as Aspen Australia celebrated their 25-year anniversary.

Alphamed Work Journal Series

The Alphamed Work Journal series captures the insights, experiences, and reflections of Aspen Global Incorporated (AGI) colleagues participating in international upskilling programmes.

Aspen concludes an exclusive Women’s Health portfolio licensing agreement with Viramal

Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmacare Holdings Limited, has entered into an exclusive licensing agreement (“Agreement”) with UK-based specialist pharmaceutical company Viramal Limited (“Viramal”) for an innovative Women’s Health portfolio. Under the agreement, Aspen will have exclusive rights to launch and commercialize selected products from Viramal’s portfolio in Europe, the Middle East, Brazil and Mexico.

A United Approach to Tackling Obesity

Obesity is far more than a medical condition — it is a complex societal challenge that affects individuals, families, communities, and the broader healthcare system in South Africa. Its growing prevalence is shaped by a mix of biological, environmental, and socioeconomic factors, making it an issue that cannot be addressed through personal effort alone.

Aspen Ireland gets recognised for their efforts in diversity

Congratulations to Aspen Ireland for being accredited with the Investors in Diversity Silver award.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: